trending Market Intelligence /marketintelligence/en/news-insights/trending/9N2E7QfMKx9_Sh1guflO9w2 content esgSubNav
In This List

Fresenius Medical, NxStage merger further delayed pending FTC decision

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Fresenius Medical, NxStage merger further delayed pending FTC decision

The merger between Fresenius Medical Care AG & Co. KGaA and NxStage Medical Inc., a transaction valued at $2 billion, has been further delayed as the companies await a decision from the Federal Trade Commission.

The companies have been working with the regulatory agency to obtain clearance for the transaction, which was previously extended from Aug. 7, 2018, to Nov. 5, 2018. According to a Jan. 2 regulatory document from Fresenius Medical, the transaction is now expected to be completed in early 2019.

While Fresenius did not cite the federal government shutdown, the FTC has been closed and operating on a limited basis since Dec. 28, 2018.

Lawrence, Mass.-based NxStage, which develops medical devices for home dialysis, delivered $394 million in revenue in 2017. Its shareholders approved the merger and will receive $30 in cash for each common share of NxStage.

Germany-based Fresenius Medical provides services for kidney-related diseases, including dialysis treatment, diagnostics and outpatient care.